ULTOMIRIS (ravulizumab-cwvz) injection

ULTOMIRIS is a prescription medicine used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Brand name: ULTOMIRIS (ravulizumab-cwvz) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018. FDA approved ravulizumab-cwvz (brand name ULTOMIRIS) is not (yet) registered or available in India but on request Indian patient can buy ULTOMIRIS at the lowest price.

Home | ravulizumab-cwvz injection

ULTOMIRIS (ravulizumab-cwvz) injection Price In India and Overseas
ULTOMIRIS (ravulizumab-cwvz) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

ULTOMIRIS (ravulizumab-cwvz) injection

Ravulizumab-cwvz injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). This medicine helps reduce red blood cell destruction or breakdown (hemolysis) in patients with PNH.

ULTOMIRIS is a complement inhibitor indicated for:
• the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
• the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) .

In the United States, ravulizumab is indicated for the treatment of adults and children one month of age and older with paroxysmal nocturnal hemoglobinuria and for the treatment of adults and children one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).[4][6]

In the European Union, ravulizumab is indicated in the treatment of adults with paroxysmal nocturnal haemoglobinuria:
• in people with haemolysis with clinical symptom(s) indicative of high disease activity
• in people who are clinically stable after having been treated with eculizumab for at least the past six months.

Drug (Brand / Generic): ULTOMIRIS / ravulizumab-cwvz
Current Indications: paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)
Marketed by:: Alexion Pharmaceuticals, Inc.
Approval Date: 2018

Dosage forms and strengths of ULTOMIRIS (ravulizumab-cwvz) injection
Intravenous
Injection: 300 mg/30 mL (10 mg/mL) solution in a single-dose vial.
Injection: 300 mg/3 mL (100 mg/mL) solution in a single-dose vial.
Injection: 1,100 mg/11 mL (100 mg/mL) solution in a single-dose vial.
Subcutaneous
Injection: 245 mg/3.5 mL (70 mg/mL) solution in a single-dose prefilled
cartridge for use only with supplied single-use on-body injector.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.